Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/effect-of-eribulin-with-or-without-pembrolizumab-on-progression-free-RIHuvnNzTK
References (25)
-
R. Salgado, R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen, G. Pruneri, S. Wienert, G. Eynden, F. Baehner, F. Penault-Llorca, E. Perez, E. Thompson, W. Symmans, A. Richardson, J. Brock, C. Criscitiello, H. Bailey, M. Ignatiadis, G. Floris, J. Sparano, Z. Kos, T. Nielsen, D. Rimm, K. Allison, J. Reis-Filho, S. Loibl, C. Sotiriou, G. Viale, S. Badve, S. Adams, K. Willard-Gallo, S. Loi (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.Annals of oncology : official journal of the European Society for Medical Oncology, 26 2
-
S. Tolaney, C. Savulsky, G. Aktan, D. Xing, A. Almonte, V. Karantza, S. Diab (2017)
Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancerEuropean Journal of Cancer, 72
-
B. Szekely, V. Bossuyt, Xiaotong Li, V. Wali, G. Patwardhan, Courtney Frederick, Andrea Silber, Tristen Park, M. Harigopal, V. Pelekanou, Meiling Zhang, Qin Yan, D. Rimm, G. Bianchini, C. Hatzis, Lajos Pusztai (2018)
Immunological differences between primary and metastatic breast cancerAnnals of Oncology, 29
-
L. Dirix, I. Takács, G. Jerusalem, P. Nikolinakos, H. Arkenau, A. Forero-Torres, R. Boccia, M. Lippman, R. Somer, M. Šmakal, L. Emens, B. Hrinczenko, W. Edenfield, J. Gurtler, A. Heydebreck, H. Grote, K. Chin, E. Hamilton (2017)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyBreast Cancer Research and Treatment, 167
-
H. Rugo, J. Delord, S. Im, P. Ott, S. Piha-Paul, Philippe Bédard, J. Sachdev, C. Tourneau, E. Brummelen, A. Varga, R. Salgado, S. Loi, S. Saraf, Dina Pietrangelo, V. Karantza, A. Tan (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast CancerClinical Cancer Research, 24
-
F. Bertucci, C. Ng, A. Patsouris, N. Droin, S. Piscuoglio, N. Carbuccia, J. Soria, A. Dien, Y. Adnani, M. Kamal, S. Garnier, G. Meurice, M. Jimenez, S. Dogan, B. Verret, M. Chaffanet, T. Bachelot, M. Campone, C. Lefeuvre, H. Bonnefoi, F. Dalenc, A. Jacquet, M. Filippo, N. Babbar, D. Birnbaum, T. Filleron, C. Tourneau, F. André (2019)
Genomic characterization of metastatic breast cancersNature, 569
-
R. Nanda, Minetta Liu, C. Yau, Rebecca Shatsky, L. Pusztai, A. Wallace, A. Chien, A. Forero-Torres, E. Ellis, Heather Han, A. Clark, K. Albain, J. Boughey, N. Jaskowiak, A. Elias, C. Isaacs, K. Kemmer, T. Helsten, M. Majure, E. Stringer-Reasor, C. Parker, Marie Lee, T. Haddad, Ronald Cohen, S. Asare, Amy Wilson, G. Hirst, R. Singhrao, K. Steeg, A. Asare, J. Matthews, S. Berry, A. Sanil, R. Schwab, W. Symmans, L. Veer, D. Yee, A. DeMichele, N. Hylton, M. Melisko, J. Perlmutter, H. Rugo, D. Berry, L. Esserman (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.JAMA oncology
-
K. Hutchinson, S. Yost, Ching-Wei Chang, Radia Johnson, Adrian Carr, P. Mcadam, D. Halligan, Chun-Chieh Chang, D. Schmolze, Jackson Liang, Yuan Yuan (2019)
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype ShiftsClinical Cancer Research, 26
-
Tolaney (2018)
Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancerCancer Res, 78
-
P. Kaufman, A. Awada, C. Twelves, L. Yelle, E. Perez, G. Velikova, M. Olivo, Yi He, C. Dutcus, J. Cortés (2015)
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneJournal of Clinical Oncology, 33
-
S. Ueda, T. Saeki, H. Takeuchi, T. Shigekawa, T. Yamane, I. Kuji, A. Osaki (2016)
In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumabBritish Journal of Cancer, 114
-
R. Nanda, Minetta Liu, C. Yau, S. Asare, N. Hylton, Laura Veer, J. Perlmutter, A. Wallace, A. Chien, A. Forero-Torres, E. Ellis, Heather Han, Amy Clark, K. Albain, Judy Boughey, A. Elias, D. Berry, D. Yee, A. DeMichele, L. Esserman (2017)
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.Journal of Clinical Oncology, 35
-
E. Mittendorf, A. Philips, F. Meric-Bernstam, N. Qiao, Yun Wu, S. Harrington, X. Su, Ying Wang, A. González-Angulo, A. Akcakanat, A. Chawla, M. Curran, P. Hwu, P. Sharma, J. Litton, J. Molldrem, G. Alatrash (2014)
PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2
-
S. Adams, P. Schmid, H. Rugo, E. Winer, D. Loirat, A. Awada, D. Cescon, H. Iwata, M. Campone, R. Nanda, R. Hui, G. Curigliano, G. Curigliano, D. Toppmeyer, J. O’Shaughnessy, J. O’Shaughnessy, S. Loi, S. Paluch-Shimon, A. Tan, D. Card, J. Zhao, V. Karantza, J. Cortés (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 studyAnnals of Oncology, 30
-
T. Gruosso, M. Gigoux, V. Manem, N. Bertos, D. Zuo, Irina Perlitch, S. Saleh, Hong Zhao, Margarita Souleimanova, Radia Johnson, A. Monette, V. Ramos, M. Hallett, J. Stagg, R. Lapointe, A. Omeroglu, S. Meterissian, L. Buisseret, G. Eyden, R. Salgado, M. Guiot, Benjamin Haibe-Kains, Morag Park (2019)
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancersJournal of Clinical Investigation, 129
-
C. Denkert, G. Minckwitz, S. Darb-Esfahani, B. Lederer, B. Heppner, K. Weber, J. Budczies, J. Huober, F. Klauschen, J. Furlanetto, W. Schmitt, J. Blohmer, T. Karn, B. Pfitzner, S. Kümmel, K. Engels, A. Schneeweiss, A. Hartmann, A. Noske, P. Fasching, C. Jackisch, M. Mackelenbergh, P. Sinn, C. Schem, C. Hanusch, M. Untch, S. Loibl (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.The Lancet. Oncology, 19 1
-
P. Schmid, S. Adams, H. Rugo, A. Schneeweiss, C. Barrios, H. Iwata, V. Diéras, R. Hegg, S. Im, G. Wright, V. Henschel, L. Molinero, S. Chui, R. Funke, A. Husain, E. Winer, S. Loi, L. Emens (2018)
Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast CancerThe New England Journal of Medicine, 379
-
(2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium.Cancer discovery, 7 8
-
M. Dolled-Filhart, Darren Locke, Tiffany Murphy, F. Lynch, J. Yearley, D. Frisman, R. Pierce, R. Weiner, Dianna Wu, K. Emancipator (2016)
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.Archives of pathology & laboratory medicine, 140 11
-
Taku Yoshida, Y. Ozawa, Takayuki Kimura, Yoshiaki Sato, G. Kuznetsov, Shanqin Xu, Mai Uesugi, S. Agoulnik, Noel Taylor, Y. Funahashi, J. Matsui (2014)
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) statesBritish Journal of Cancer, 110
-
S. Adams, M. Gatti-Mays, K. Kalinsky, L. Korde, E. Sharon, L. Amiri-Kordestani, H. Bear, H. McArthur, E. Frank, J. Perlmutter, D. Page, B. Vincent, J. Hayes, J. Gulley, J. Litton, G. Hortobagyi, S. Chia, I. Krop, J. White, J. Sparano, M. Disis, E. Mittendorf (2019)
Current Landscape of Immunotherapy in Breast Cancer: A Review.JAMA oncology
-
S. Adams, S. Loi, D. Toppmeyer, D. Cescon, M. Laurentiis, R. Nanda, E. Winer, H. Mukai, K. Tamura, A. Armstrong, Minetta Liu, H. Iwata, L. Ryvo, P. Wimberger, H. Rugo, A. Tan, L. Jia, Y. Ding, V. Karantza, P. Schmid (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 studyAnnals of Oncology, 30
-
Stephen Luen, Balaji Virassamy, P. Savas, R. Salgado, S. Loi (2016)
The genomic landscape of breast cancer and its interaction with host immunity.Breast, 29
-
J. Cortés, D. Cescon, H. Rugo, Z. Nowecki, S. Im, M. Yusof, C. Gallardo, O. Lipatov, C. Barrios, E. Holgado, H. Iwata, N. Masuda, M. Otero, E. Gokmen, S. Loi, Zifang Guo, Jing Zhao, G. Aktan, V. Karantza, P. Schmid (2020)
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.Journal of Clinical Oncology, 38
-
G. Hanna, Patrick Lizotte, Megan Cavanaugh, F. Kuo, Priyanka Shivdasani, Alexander Frieden, N. Chau, J. Schoenfeld, J. Lorch, R. Uppaluri, L. Macconaill, R. Haddad (2018)
Frameshift events predict anti-PD-1/L1 response in head and neck cancer.JCI insight, 3 4
- Publisher
- American Medical Association
- Copyright
- Copyright 2020 American Medical Association. All Rights Reserved.
- ISSN
- 2374-2437
- eISSN
- 2374-2445
- DOI
- 10.1001/jamaoncol.2020.3524
- Publisher site
- See Article on Publisher Site
Abstract
This phase 2 randomized clinical trial compares the efficacy of eribulin plus pembrolizumab vs eribulin alone in hormone receptor–positive, ERBB2-negative metastatic breast cancer.
Journal
JAMA Oncology – American Medical Association
Published: Oct 3, 2020